Patents Assigned to Purdue Pharmaceutical Products, L.P.
  • Patent number: 10744120
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 18, 2020
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Patent number: 10507205
    Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Lars Hermann
  • Patent number: 10406138
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 10, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Patent number: 10118901
    Abstract: The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 6, 2018
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Yu Chen, Yi Chen
  • Patent number: 9993482
    Abstract: The present invention is directed to a combination comprising a class III receptor tyrosine kinase inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Thomas Jorg Mehrling
  • Publication number: 20170296513
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 26, 2015
    Publication date: October 19, 2017
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Publication number: 20170151218
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 26, 2015
    Publication date: June 1, 2017
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Publication number: 20170128741
    Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Llew KELTNER, Jay WINSHIP, Erik HAGSTROM, Frank ZHENG, James C. CHEN, Joseph M. HOBBS
  • Publication number: 20160213945
    Abstract: A photoreactive agent and a drug therapy device including a support member configured to pass through a urethra having proximal and distal ends and a longitudinal internal lumen. A light generator carried by the support member, potted within the lumen, and positioned within the urethra to deliver light to the prostate. The light generator generates a light band with a peak at a preselected wavelength. A power source external to the support member powers the light generator. The positioning element locates the support member within the urethra. A transparent/translucent, integral window is positioned proximate to the prostate and allows light to pass through. The window extends 360 degrees radially from the support member. The light generator has at least LEDs or LOs having a dimension of approximately 0.3 mm×0.3 mm×0.1 mm (length×width×thickness).
    Type: Application
    Filed: April 5, 2016
    Publication date: July 28, 2016
    Applicant: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Phillip Burwell, Zihong Guo, Jennifer K. Matson, Steven Ross Daly, David B. Shine, Gary Lichttenegger, Jean Bishop, Nick Yeo, Hugh Narciso, Llew Keltner, Jay Winship, Erik Hagstrom, Frank Zheng, James C. Chen, Joseph M. Hobbs
  • Patent number: 9376395
    Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 28, 2016
    Assignee: Purdue Pharmaceuticals Products L.P.
    Inventors: Yu Chen, Lan Yang, Feiyu Feng, Qiufu Ge, Dianwu Guo, Yi Chen
  • Patent number: 9149651
    Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: October 6, 2015
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Llew Keltner, James C. Chen
  • Patent number: 9096627
    Abstract: The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: August 4, 2015
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Yu Chen, Yi Chen
  • Publication number: 20150183747
    Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 2, 2015
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Yu Chen, Lan Yang, Feiyu Feng, Qiufu Ge, Dianwu Guo, Yi Chen
  • Patent number: 8962855
    Abstract: The disclosure includes compounds of Formula (1): wherein X1, X2, Q, Z, R1, and R2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: February 24, 2015
    Assignee: Purdue Pharmaceutical Products, L.P.
    Inventors: Yu Chen, Yi Chen
  • Patent number: 8822677
    Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product (Formula I). This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: September 2, 2014
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Leon Xu, Alexander J. Pallenberg
  • Patent number: 8685005
    Abstract: A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: April 1, 2014
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Jonathan S. Dahm, William Louis Barnard, James C. Chen, David B. Shine
  • Patent number: 8685071
    Abstract: A method of manufacture and medical apparatus that provides an apparatus useful in illuminating at least a portion of a lumen of a body. The apparatus includes an elongated flexible member and a polymer encasement portion encasing a plurality of light emitters. The light emitters may be electrically coupled to one another without the use of wire bonds, and in some embodiments may be coupled without intervening electrical paths or traces. A maximum cross-sectional dimension of the polymer encasement portion may be less than twice a dimension of one of the light emitters. In some embodiments the maximum cross-sectional dimension is less than or equal to the sum of the dimension of one of the light emitters and a marginal dimension by which an outer portion of the polymer encasement portion extends beyond the light emitter. Light emitters may be arranged linearly, helically or in partially overlapping back-to-back relation.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: April 1, 2014
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Phillip Burwell, James C. Chen, Zihong Guo, Steven R. Daly, David B. Shine, Gary Lichttenegger, Jennifer K. Matson, Jean Bishop, Nick Yeo, Hugh Narciso
  • Publication number: 20140066419
    Abstract: The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Yu Chen, Yi Chen
  • Patent number: RE46144
    Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Yu Chen, Yi Chen
  • Patent number: RE46504
    Abstract: A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 8, 2017
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Jonathan S. Dahm, William Louis Barnard, James C. Chen, David B. Shine